Treatment of cancer is hampered by a paucity of suitable drug targets. Moreover, single agent therapies are rarely curative for advanced disease. Synthetic lethality holds the promise to deliver both entirely new classes of targets for cancer therapy and it allows for the identification of very effective combination therapies. This session will focus on the use of synthetic lethal genetic screens to accomplish these two goals.